Abstract
A pilot study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer has been started in Korea. Archival tumor samples were tested for HRD and PD-L1 status. Treatment arms will be allocated according to the test results. For HRD+ patients, we tested the synergistic effects of olaparib and other agents; treatment arms will randomly be allocated. (Arm 1: olaparib and cediranib; Arm 2: olaparib and durvalumab). For HRD- patients, we tested the role of biomarker-driven immunotherapy according to PD-L1 expression (Arm 3: durvalumab and chemotherapy in patients with high PD-L1 expression; Arm 4: durvalumab, tremelimumab, and chemotherapy in patients with low PD-L1 expression). Sixty-eight patients will be included from three Korean institutions within 1 year. The primary endpoint is the response rate according to RECIST 1.1 (6 months after treatment initiation). This trial has been registered with clinicaltrials.gov, and the registration number is NCT03699449.
| Original language | English |
|---|---|
| Pages (from-to) | 789-792 |
| Number of pages | 4 |
| Journal | Japanese Journal of Clinical Oncology |
| Volume | 49 |
| Issue number | 8 |
| DOIs | |
| State | Published - 1 Aug 2019 |
| Externally published | Yes |
Keywords
- Biomarker
- Ovarian cancer
- Platinum-resistant
- Targeted therapy
- Umbrella study
